Isolated hypoxic hepatic perfusion with melphalan in patients with irresectable ocular melanoma metastases

European Journal of Surgical Oncology

Volumn 35, Issue 5, 2009, Pages 539-545

  van Etten, B ^a   de Wilt, J H W ^a   Brunstein, F ^a   Eggermont, A M M ^a   Verhoef, C ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Hepatic metastasis; Isolated perfusion; Melanoma; Melphalan

Indexed keywords

MELPHALAN;

ADULT; AGED; ARTICLE; BILE DUCT DISEASE; BILE DUCT NECROSIS; BLEEDING; BLOOD CLOTTING DISORDER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CANCER THERAPY; CHOLECYSTITIS; CLINICAL ARTICLE; CONTINUOUS INFUSION; DEHYDRATION; EYE CANCER; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; HEPATIC ARTERY; HOSPITALIZATION; HUMAN; ISOLATED HYPOXIC HEPATIC PERFUSION; LEUKOPENIA; LIVER METASTASIS; LIVER TOXICITY; MALE; MELANOMA; NEPHROTOXICITY; PORTAL VEIN; PRIORITY JOURNAL; SURGICAL MORTALITY; SURVIVAL TIME; TREATMENT RESPONSE; WOUND INFECTION;

AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; EYE NEOPLASMS; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MELANOMA; MELPHALAN; MIDDLE AGED; TREATMENT OUTCOME;

EID: 63049100583     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2008.07.004     Document Type: Article

References (36)

1. IKC. Dutch Cancer Registration on IKCnet.nl. 2003.
2. Isager P., Osterlind A., Engholm G., et al. Uveal and conjunctival malignant melanoma in Denmark, 1943-97: incidence and validation study. Ophthalm Epidemiol 12 4 (2005) 223-232
3. Diener-West M., Hawkins B.S., Markowitz J.A., and Schachat A.P. A review of mortality from choroidal melanoma. II. A meta-analysis of 5-year mortality rates following enucleation, 1966 through 1988. Arch Ophthalmol 110 2 (1992) 245-250
4. Seregard S., and Kock E. Prognostic indicators following enucleation for posterior uveal melanoma. A multivariate analysis of long-term survival with minimized loss to follow-up. Acta Ophthalmol Scand 73 4 (1995) 340-344
5. COMS. Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS report no. 15. Arch Ophthalmol 119 5 (2001) 670-676
6. Gragoudas E.S., Egan K.M., Seddon J.M., et al. Survival of patients with metastases from uveal melanoma. Ophthalmology 98 3 (1991) 383-389 discussion 90
7. Avril M.F., Aamdal S., Grob J.J., et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol 22 6 (2004) 1118-1125
8. Kivela T., Suciu S., Hansson J., et al. Bleomycin, vincristine, lomustine and dacarbazine (BOLD) in combination with recombinant interferon alpha-2b for metastatic uveal melanoma. Eur J Cancer 39 8 (2003) 1115-1120
9. Pyrhonen S., Hahka-Kemppinen M., Muhonen T., et al. Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD), and human leukocyte interferon for metastatic uveal melanoma. Cancer 95 11 (2002) 2366-2372
10. Bedikian A.Y., Kantarjian H., Young S.E., and Bodey G.P. Prognosis in metastatic choroidal melanoma. South Med J 74 5 (1981) 574-577
11. Hsueh E.C., Essner R., Foshag L.J., Ye X., Wang H.J., and Morton D.L. Prolonged survival after complete resection of metastases from intraocular melanoma. Cancer 100 1 (2004) 122-129
12. Pawlik T.M., Zorzi D., Abdalla E.K., et al. Hepatic resection for metastatic melanoma: distinct patterns of recurrence and prognosis for ocular versus cutaneous disease. Ann Surg Oncol 13 5 (2006) 712-720
13. Rivoire M., Kodjikian L., Baldo S., Kaemmerlen P., Negrier S., and Grange J.D. Treatment of liver metastases from uveal melanoma. Ann Surg Oncol 12 6 (2005) 422-428
14. Agarwala S.S., Panikkar R., and Kirkwood J.M. Phase I/II randomized trial of intrahepatic arterial infusion chemotherapy with cisplatin and chemoembolization with cisplatin and polyvinyl sponge in patients with ocular melanoma metastatic to the liver. Melanoma Res 14 3 (2004) 217-222
15. Peters S., Voelter V., Zografos L., et al. Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: experience in 101 patients. Ann Oncol 17 4 (2006) 578-583
16. Siegel R., Hauschild A., Kettelhack C., Kahler K.C., Bembenek A., and Schlag P.M. Hepatic arterial Fotemustine chemotherapy in patients with liver metastases from cutaneous melanoma is as effective as in ocular melanoma. Eur J Surg Oncol 33 5 (2007) 627-632
17. Bartlett D.L., Libutti S.K., Figg W.D., Fraker D.L., and Alexander H.R. Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer. Surgery 129 2 (2001) 176-187
18. de Vries M.R., Borel Rinkes I.H., van de Velde C.J., et al. Isolated hepatic perfusion with tumor necrosis factor alpha and melphalan: experimental studies in pigs and phase I data from humans. Recent Results Cancer Res 147 (1998) 107-119 (Fortschritte der Krebsforschung)
19. de Wilt J.H., van Etten B., Verhoef C., and Eggermont A.M. Isolated hepatic perfusion: experimental evidence and clinical utility. Surg Clin North Am 84 2 (2004) 627-641
20. Rothbarth J., Pijl M.E., Vahrmeijer A.L., et al. Isolated hepatic perfusion with high-dose melphalan for the treatment of colorectal metastasis confined to the liver. Br J Surg 90 11 (2003) 1391-1397
21. Alexander H.R., Libutti S.K., Bartlett D.L., Puhlmann M., Fraker D.L., and Bachenheimer L.C. A phase I-II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liver. Clin Cancer Res 6 8 (2000) 3062-3070
22. Alexander Jr. H.R., Libutti S.K., Pingpank J.F., et al. Hyperthermic isolated hepatic perfusion using melphalan for patients with ocular melanoma metastatic to liver. Clin Cancer Res 9 17 (2003) 6343-6349
23. Hafstrom L., and Naredi P. Isolated hepatic perfusion with extracorporeal oxygenation using hyperthermia TNF alpha and melphalan: Swedish experience. Recent Results Cancer Res 147 (1998) 120-126 (Fortschritte der Krebsforschung)
24. Lindner P., Fjalling M., Hafstrom L., et al. Isolated hepatic perfusion with extracorporeal oxygenation using hyperthermia, tumour necrosis factor alpha and melphalan. Eur J Surg Oncol 25 2 (1999) 179-185
25. Noter S.L., Rothbarth J., Pijl M.E., et al. Isolated hepatic perfusion with high-dose melphalan for the treatment of uveal melanoma metastases confined to the liver. Melanoma Res 14 1 (2004) 67-72
26. van Etten B., Brunstein F., van IJken M.G., et al. Isolated hypoxic hepatic perfusion with orthograde or retrograde flow in patients with irresectable liver metastases using percutaneous balloon catheter techniques: a phase I and II study. Annals Surg Oncol 11 6 (2004) 598-605
27. Verhoef C., JHW de W., Brunstein F., et al. Isolated hypoxic hepatic perfusion with retrograde outflow in patients with irresectable liver metastases; A New Simplified Technique in Isolated Hepatic Perfusion. Annals Surg Oncol 15 5 (2008) 1367-1374
28. Hafstrom L.R., Holmberg S.B., Naredi P.L., et al. Isolated hyperthermic liver perfusion with chemotherapy for liver malignancy. Surg Oncol 3 2 (1994) 103-108
29. Oldhafer K.J., Frerker M.K., Lang H., et al. High-dose mitomycin C in isolated hyperthermic liver perfusion for unresectable liver metastases. J Invest Surg 11 6 (1998) 393-400
30. Eggermont A.M., Schraffordt Koops H., Klausner J.M., et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg 224 6 (1996) 756-64 (discussion 64-5)
31. Verhoef C., de Wilt J.H., Grunhagen D.J., van Geel A.N., Ten Hagen T.L., and Eggermont A.M. Isolated limb perfusion with melphalan and TNF-alpha in the treatment of extremity sarcoma. Curr Treat Options Oncol 8 6 (2007) 417-427
32. van Etten B., de Vries M.R., van IJken M.G., et al. Degree of tumour vascularity correlates with drug accumulation and tumour response upon TNF-alpha-based isolated hepatic perfusion. Br J Cancer 88 2 (2003) 314-319
33. Alexander Jr. H.R., Bartlett D.L., Libutti S.K., Fraker D.L., Moser T., and Rosenberg S.A. Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. J Clin Oncol 16 4 (1998) 1479-1489
34. Brunstein F., Eggermont A.M., de Wiel-Ambagtsheer G., van Tiel S.T., Rens J., and ten Hagen T.L. Synergistic antitumor effects of histamine plus melphalan in isolated hepatic perfusion for liver metastases. Annals Surg Oncol 14 2 (2007) 795-801
35. Hoving S. Brunstein F, aan de Wiel-Ambagtsheer G, et al. Synergistic antitumor response of interleukin 2 with melphalan in isolated limb perfusion in soft tissue sarcoma-bearing rats. Cancer Res 65 10 (2005) 4300-4308
36. Verheul H.M.W., Salumbides B., vanErp K., et al. Combination strategy targeting the Hypoxia Inducible Factor-1A with mammalian target of rapamycin and histone deacetylase inhibitors. Clin Cancer Res 14 11 (2008) 3589-3597